Portal de Periódicos da CAPES

Cross-reactivity between carbapenems: Two case reports

2014; Elsevier BV; Volume: 2; Issue: 6 Linguagem: Inglês

10.1016/j.jaip.2014.06.015

2213-2201

Blanca Noguerado-Mellado, Celia Pinto Fernández, Rafael Pineda-Pineda, Patricia Martínez Lezcano, Alberto Álvarez‐Perea, Manuel De Barrio Fernández,

Pneumocystis jirovecii pneumonia detection and treatment

Carbapenems (imipenem, meropenem, and ertapenem) (Figure 1) are broad-spectrum β-lactam antibiotics. They are typically used as second-line treatment for severe polymicrobial and resistant bacterial infections in hospitals. The antimicrobial spectrum of imipenem and meropenem is similar, with coverage of most of the gram-positive cocci, gram-negative bacilli, and anaerobic microorganisms.1 Imipenem is inactivated in the kidneys and produces a nephrotoxic metabolite, so it is formulated (in 1:1 proportion) with cilastatin, an enzymatic inhibitor of human dehydropeptidase-I, that blocks its metabolism in the kidneys, which increases levels of drug in the urine and reduces its toxicity.